Tenofovir Alafenamide Fumarate (TAF) effect on residual intrathecal immune activation

Trial Profile

Tenofovir Alafenamide Fumarate (TAF) effect on residual intrathecal immune activation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Jan 2018 Planned End Date changed from 1 Oct 2017 to 31 Mar 2018.
    • 02 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top